Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
8
80%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
8(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 28 (80.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

NCT00267592
terminatedphase_2

Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00982150
completedphase_2

Talampanel in Treating Patients With Recurrent High-Grade Glioma

NCT00064363
completedphase_2

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00696332
terminatedphase_2

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

NCT00062504
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00267592Phase 2

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Completed
NCT00982150Phase 2

Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT00064363Phase 2

Talampanel in Treating Patients With Recurrent High-Grade Glioma

Completed
NCT00696332Phase 2

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT00062504Phase 2

Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas

Terminated
NCT00036296Phase 1

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Completed
NCT00034814Phase 2

Multicenter Trial for Adults With Partial Seizures

Completed
NCT00964730Phase 1

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Completed
NCT00108667Phase 2

Talampanel to Treat Parkinson's Disease

Completed
NCT00057460Phase 2

Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10